Results
There was no significant difference between patients treated with the experimental therapy of paclitaxel plus carboplatin and control treatments over a median follow-up period of 51 months. There was no significant difference in the occurrence of the secondary endpoint of progression-free survival.
There were differences in side-effect profiles:
- paclitaxel plus carboplatin caused more alopecia, fever and sensory neuropathy than carboplatin alone
- paclitaxel plus carboplatin caused more sensory neuropathy than CAP
- CAP caused more fever than paclitaxel plus carboplatin
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.